Clinical Ink Appoints Stephen Boccardo as Chief Commerical Officer

WINSTON-SALEM, NC and PHILADELPHIA, PA--(Marketwired - March 10, 2016) - Clinical Ink, the pioneering provider of eSource solutions for clinical trials, announced that Stephen Boccardo has joined the company as Chief Commercial Officer (CCO). In this newly created role, Mr. Boccardo is responsible for leading all Clinical Ink commercial activities, including the global sales and marketing teams. He reports directly to Clinical Ink CEO, Ed Seguine.

"Steve's expertise at managing high-performing business development organizations will enhance our position as an eSource and Patient Engagement pioneer and industry leader," said Ed Seguine, CEO, Clinical Ink. "His proven ability to build and lead commercial teams and to successfully drive new business will be essential to extend our track record of invention and usability, fueled by rapid growth."

Mr. Boccardo brings more than 20 years of domain experience in the life science industry with specific expertise in management, business development and information technologies. Mr. Boccardo joined Clinical Ink from Bioclinica where he served as Senior Vice President, Global Business Development for the company's eClinical Solutions Division. As part of the executive team at Bioclinica, Mr. Boccardo led the sales and marketing departments, generating record results in both the US and Europe.

"I'm excited to join Clinical Ink and maximize the commercial potential of the most widely-used eSource solution on the market today," said Stephen Boccardo, Chief Commercial Officer, Clinical Ink. "In the effort to streamline and modernize clinical investigations, paper source and EDC have continued to frustrate meaningful advances. The process at sites for capturing clinical information during a trial has not changed in the past fifty years and site professionals are keenly aware of this. Capturing source data in electronic form, using Clinical Ink's SureSource system, ensures the reliability, quality, integrity, and traceability of data from electronic source to electronic regulatory submission, and finally delivers the benefits of technology that legacy systems do not. Clinical site personnel report a savings of 30%-40% of their time when they do not have to transcribe source data into EDC. In addition, since all source is electronic, you eliminate the need for on-site source data verification, allowing for true remote monitoring saving time and money while increasing quality."

"Our innovation doesn't stop at the site. Clinical Ink's CentrosHealth technology is the first of its kind platform that allows business users the ability to configure and deploy Patient Engagement apps to any device (BYOD). From tasks and daily reminders to diary capture and sensor integration, CentrosHealth is leading the way towards a more Patient Centric approach to clinical trials. I look forward to helping more life science companies improve their clinical trial efficiency and patient engagement with innovative technologies that make research easier -- for sites, sponsors and patients." 

About Clinical Ink

Founded in 2007, Clinical Ink is transforming clinical development -- from Start to Submit -- with a completely paperless clinical trial platform for sites, sponsors, CROs and patients. Clinical Ink's SureSource and CentrosHealth technology solutions directly capture eSource data and documents and improve patient engagement while streamlining clinical development. Clinical Ink maintains offices in Winston-Salem, NC, and Philadelphia, PA. Additional information is available online at www.clinicalink.com.